RBC Capital downgrades Aardvark Therapeutics stock rating on trial pause
#Aardvark Therapeutics#RBC Capital#ARD-101#Prader-Willi syndrome#Phase III trial#Stock downgrade#FDA approval#Clinical safety
📌 Key Takeaways
RBC Capital downgraded Aardvark Therapeutics stock rating to Sector Perform from Outperform and cut price target to $6 from $18
The downgrade follows Aardvark's pause of its Phase III study of ARD-101 due to cardiac observations in healthy subjects
Clean safety was observed at therapeutic doses, potentially allowing a path forward for the drug
Timelines will likely be pushed back as the company engages with the FDA on next steps
Despite the clinical pause, Aardvark maintains a strong balance sheet with a current ratio of 12.03
📖 Full Retelling
RBC Capital downgraded Aardvark Therapeutics Inc (NASDAQ:AARD) stock to Sector Perform from Outperform and slashed its price target to $6.00 from $18.00 on February 3, 2026, following the biopharmaceutical company's announcement of a voluntary pause in its Phase III study of lead drug ARD-101 for Prader-Willi syndrome due to cardiac observations in a separate study of healthy subjects. The stock currently trades at $12.49, significantly above the new price target but below the analyst high target of $47. The downgrade comes after Aardvark Therapeutics voluntarily paused its Phase 3 HERO trial for ARD-101, which focuses on hyperphagia in Prader-Willi Syndrome, following reversible cardiac observations noted at doses above the target therapeutic levels. RBC Capital analysts had the opportunity to speak with management following the announcement and noted that clean safety was observed at therapeutic doses, potentially allowing a path forward for the drug. However, the firm emphasized that timelines will likely be pushed back significantly as the company engages with the FDA on next steps, adding uncertainty to what was considered the lower-risk element of the program's profile, its acute safety.
The phases of clinical research are the stages in which scientists conduct experiments with a health intervention to obtain sufficient evidence for a process considered effective as a medical treatment. For drug development, the clinical phases start with testing for drug safety in a few human subje...
RBC Capital Markets is a global investment bank providing services in banking, finance, and capital markets to corporations, institutional investors, asset managers, and governments globally. Locations span 55 offices in 15 countries across North America, the UK, Europe, and the Asia-Pacific region....
# Food and Drug Administration (FDA)
The **Food and Drug Administration (FDA)** is a federal agency within the **United States Department of Health and Human Services (HHS)**. It serves as the primary regulatory body responsible for protecting and promoting public health in the United States.
### ...
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Asia stocks slide as US-Iran strikes batter risk appetite Oil prices surge after US-Israel strikes on Iran, trim early gains Gold prices jump 2% amid widening US-Israel conflict with Iran Middle East tensions rise as Iran promises retaliation (South Africa Philippines Nigeria) RBC Capital downgrades Aardvark Therapeutics stock rating on trial pause By Investing.com Analyst Ratings Published 03/02/2026, 01:31 AM RBC Capital downgrades Aardvark Therapeutics stock rating on trial pause 0 AARD -0.08% Investing.com - RBC Capital downgraded Aardvark Therapeutics Inc (NASDAQ:AARD) to Sector Perform from Outperform and cut its price target to $6.00 from $18.00. The stock currently trades at $12.49, well above the new target but below the analyst high target of $47. The downgrade follows Aardvark’s announcement Friday evening of a voluntary pause of its ongoing Phase III study of lead drug ARD-101 for Prader-Willi syndrome due to cardiac observations in a separate study of healthy subjects. RBC Capital said it had the chance to speak with management following the announcement. The firm noted that clean safety was seen at therapeutic doses, which may still allow a path forward for the drug. The firm said timelines will likely be pushed back meaningfully as the company engages with the FDA on next steps. The development adds a layer of uncertainty to what was considered the lower-risk element of the program’s profile, its acute safety. RBC Capital said it is stepping to the sidelines pending further clarity on the situation.The clinical pause comes as Aardvark maintains a strong balance sheet with a current ratio of 12.03 and holds more cash than debt, though InvestingPro notes the company is quickly burning through cash with negative free cash flow of $45 million. The platform’s Fair Value analysis suggests the stock is slightly overvalued at current levels, with 9 additional ProTips available to subscribers. In other ...
